N
PRLD icon

Nuveen’s Prelude Therapeutics PRLD Stock Holding History

Nuveen’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-187,613
Closed -$3.62M – 3376
2025
Q1 		$3.62M Buy
187,613
+170,816
+1,017% +$159K ﹤0.01% 2080
2024
Q4 		$21.4K Hold
16,797
– – ﹤0.01% 3322
2024
Q3 		$34.8K Hold
16,797
– – ﹤0.01% 3328
2024
Q2 		$64K Hold
16,797
– – ﹤0.01% 3320
2024
Q1 		$79.6K Hold
16,797
– – ﹤0.01% 3257
2023
Q4 		$71.7K Buy
16,797
+2,993
+22% +$9.11K ﹤0.01% 3297
2023
Q3 		$42.7K Hold
13,804
– – ﹤0.01% 3160
2023
Q2 		$62.1K Buy
+13,804
New +$82.5K ﹤0.01% 3184
2022
Q2 		– Sell
-66,421
Closed -$490K – 3439
2022
Q1 		$490K Buy
66,421
+25,904
+64% +$237K ﹤0.01% 3024
2021
Q4 		$504K Sell
40,517
-4,882
-11% -$79.4K ﹤0.01% 3072
2021
Q3 		$1.42M Buy
45,399
+8,240
+22% +$267K ﹤0.01% 2832
2021
Q2 		$1.06M Sell
37,159
-187
-0.5% -$6.66K ﹤0.01% 2982
2021
Q1 		$1.62M Buy
37,346
+2,624
+8% +$174K ﹤0.01% 2711
2020
Q4 		$2.48M Buy
+34,722
New +$1.73M ﹤0.01% 2404

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Nuveen's PRLD Position: Q2 2025 in Review

Nuveen sold out of Prelude Therapeutics (PRLD) in Q2 2025, closing a stake of 187,613 shares — an estimated $3.62M sold.

Nuveen first reported a position in PRLD in Q4 2020 and held it in 14 quarters. The position peaked at $3.62M in Q1 2025. 50 funds tracked by Wall St. Rank hold PRLD as of Q2 2025.

  • Nuveen reported no remaining Prelude Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Nuveen sold 187,613 Prelude Therapeutics shares in Q2 2025, an estimated $3.62M.
  • Nuveen first reported a position in Prelude Therapeutics in Q4 2020 and held it in 14 quarters.
  • Nuveen's Prelude Therapeutics position peaked at $3.62M in Q1 2025.
  • 50 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.